Daily Alpha · Reddit
· Post-Market Alpha · by Buzzberg Research
Retail debate centered on the oil-and-yield squeeze, gold's failure to confirm the debasement trade, housing weakness, and single-name governance and catalyst setups.
Themes on this desk
Oil shock and rate transmission
Traders argue the oil spike and 4.9% 10-year yield cap equity upside, with Houthi Red Sea risk and physical spot premiums above futures.
Gold debasement versus rate headwind
Bulls cite $40T debt and fiat debasement; bears counter that higher oil lifts PPI, rates and therefore gold downside. Gold's failure to rally with oil is the live test.
Small caps and crowded hedging
Russell 2000 near highs with weaker balance sheets and rate exposure draws short interest; others see put-call skew too crowded for a major drop.
Highest engagement
by score · day changeIREN rejected for dilution, $700M comp package and ATM-funded sponsorship
Commenter calls IREN a hard pass, citing nonstop shareholder dilution, a $700 million stock comp package for the two brothers running the company with nothing tied to performance, and a $50 million Golden State Warriors sponsorship funded through a $6 billion ATM; prefers CRWV for neocloud exposure and APLD as the best co-location data center provider.
Nonstop shareholder dilution. A $700 million stock comp package for the two brothers who run the company, purely dilutive, with
Dilution and governance concerns are a recurring bear case across AI-adjacent infrastructure names; if IREN's share count keeps expanding, per-share value capture from any data center buildout is diluted.
Watch IREN's share count trajectory and ATM usage in the next filing, plus whether the sponsorship and comp package show up as cash or equity outflow.
Source →BIS warns AI capex financing poses financial stability risk
Post cites a BIS warning that the scale of AI investment could create financial stability risks, estimating the five biggest tech companies could spend over $1 trillion on AI in 2025-2026 with total AI investment reaching roughly $4 trillion by 2030, and notes funding increasingly relies on debt and private credit rather than Big Tech cash flow alone.
But BIS is now warning that the scale of this investment could create risks for financial stability.
Shifts the AI trade risk from hyperscaler earnings to the creditworthiness of the debt and private-credit financiers behind data centers and power infrastructure, a systemic channel equity holders may be under-pricing.
Watch BIS follow-up statements, AI-related private credit spreads and issuance volumes, and whether hyperscaler capex guidance shifts toward off-balance-sheet financing.
Source →Google buyback halt removes prior price floor, argues against blind 200-EMA dip buying
Commenter warns against blindly buying Alphabet on the assumption it will bounce off the 200-day EMA as it did earlier in the year, arguing Google is no longer doing buybacks so the floor that once supported the stock is gone, and advises waiting for resistance/bounce confirmation at the 200 EMA rather than buying blind.
yr. Google is no longer doing buybacks. The floor that was once there is no longer flooring.
A large-cap losing its structural buyback bid changes the demand profile at technical support; if true, dip-buying strategies that worked earlier in the year are no longer reliable and downside can extend further than the 200-day EMA implies.
Watch Whether GOOGL breaks and holds below the 200-day EMA without a buyback-driven recovery, and whether Alphabet discloses any resumption or pause of repurchases in filings.
Source →Cannara Biotech expands credit facility to fund EU-GMP cultivation capacity ahead of German supply tightening
Commenter argues Cannara just increased its credit facility and is going all in on expanding cultivation capacity in preparation for applying for and obtaining EU-GMP certification, expecting compliant EU-GMP flower to become scarce as Germany cracks down on EU-GMP washing.
With Germany cracking down on EU-GMP washing, compliant EU-GMP flower will be hard to come by and will become that
If German enforcement tightens the definition of compliant EU-GMP flower, certified producers gain pricing power in the largest European medical cannabis market, making pre-certification capacity expansion a potential competitive moat.
Watch Cannara's EU-GMP certification being granted and evidence of German regulatory enforcement reducing the supply of compliant flower.
Source →Volatus Aerospace wins five-year Canadian Armed Forces drone contract
Volatus Aerospace (FLT.TO) was awarded a five-year contract to supply drones to the Canadian Armed Forces, with initial procurement of 100 tactical ISR uncrewed aircraft systems at a ceiling price of CA$5,000 each and options for up to an additional 4,900 units at the same price; contracted pricing remains confidential. CEO Glen Lynch framed it as validating an integrated model spanning payload integration, training, sustainment and technical support.
price of CA$5,000 each, with options to acquire up to an additional 4,900 units at the same price.
A multi-year sovereign defense drone program with a large option pool gives Volatus a visible revenue runway and a reference customer for scaling defense sales.
Watch Confirm follow-on option exercises and defense revenue recognition in filings; invalidation is options not being exercised or the contract being reduced.
Source →Most argued
by comments per upvoteCameco signs $2.6B uranium supply deal with India through 2035
Post states Saskatoon-based Cameco signed a $2.6 billion agreement to supply nearly 22 million pounds of uranium to India from 2027 to 2035, alongside Canada-India memoranda on critical minerals and energy supply chains.
\- Saskatoon-based Cameco signed a $2.6 billion agreement to supply nearly 22 million pounds of uranium to India from 2027
A long-dated contracted volume from a new non-US buyer supports the thesis that Canadian uranium producers are diversifying away from US utility demand and locking in multi-year pricing visibility.
Watch Confirm the contract value and poundage in Cameco disclosures or Indian government releases; track whether deliveries begin on schedule in 2027.
Source →DOJ reportedly probing Nvidia's licensing deal with Groq
A post cites an NYT report that the DOJ is investigating Nvidia's licensing arrangement with AI startup Groq under an anti-monopoly inquiry.
[Anti-monopoly inquiry] DOJ probes Nvidia's licensing deal with AI startup Groq, NYT reports
Antitrust scrutiny of Nvidia's deal structures with AI startups introduces a regulatory tail risk to how the company locks in talent and IP, potentially slowing its ability to absorb competitive threats.
Watch Track whether the DOJ opens a formal investigation, issues subpoenas, or the report is confirmed/denied by Nvidia or Groq; absence of follow-up coverage would suggest a headline-only event.
Source →Reddit alt data shows Q3 revenue growth 63% vs 49% consensus
Commenter claims Reddit has 60% revenue growth with alternative data pointing to 63% in Q3 versus 49% analyst consensus, and argues AI training data deals are coming because the CEO confirmed it at a conference.
Q3 vs the 49% analysts consensus.
A 14-point gap between alt-data and consensus growth, if real, implies a significant beat-and-raise setup for RDDT and supports the AI-licensing revenue optionality narrative.
Watch Verify against Reddit's actual Q3 print: revenue growth at or above ~60% with disclosed new AI data licensing revenue would confirm; growth near 49% or no new deals would invalidate.
Source →Boston Scientific seen cheap at 14x forward P/E after cyberattack drop
Author argues BSX looks undervalued at a forward P/E of 14 versus a 20x-25x historical range for high-moat medtech, with organic sales growth of 7% and adjusted EPS up 15% YoY in Q2, while flagging that a cyberattack drove a ~10% two-week decline and management signaled it may miss full-year guidance.
A forward P/E of 14 for a company growing organic sales at 7% and adjusted EPS at double digits (15%
Sets up a potential value entry in a large-cap medtech if the cyberattack hit is temporary, but the pre-announced guidance miss creates a near-term catalyst risk around autumn results.
Watch Watch the autumn earnings report: a guidance miss with a further selloff would validate caution, while maintained guidance and a stock rebound would confirm the mispricing thesis.
Source →OrbiMed 13F shows huge SLS put bet; hedge advised
Commenter cites Perceptive Advisors and OrbiMed's most recent 13F, noting OrbiMed made a huge put bet against SLS and that other bio majors did similar, advising SLS holders to at least hedge because 'they know more than we do.'
Perceptive Advisors & Orbimed Most recent 13F. Orbimed made a HUGE put bet against SLS.
Large specialist healthcare funds positioning via puts against a small-cap biotech is a disclosed, checkable bearish signal that retail holders may be underweighting; it is a rare instance of institutional positioning data in the source.
Watch Whether SLS underperforms into the next 13F update and whether the put position is added to or closed; a rising SLS with shrinking puts would invalidate the signal.
Source →